GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imagin
Go back to GE HealthCare Announces First Patient Dosed in Phase 2/3 LUMINA Trial for Manganese-Based MRI Contrast Agent Under FDA Fast Track Designation, Further Advancing Its Innovation Pipeline of Novel Imagin| (NASDAQ: GEHC) | Delayed: 63.72 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $63.72 | 52 Week High | $ | |||
| Open | $63.72 | 52 Week Low | $ | |||
| Day High | $63.72 | P/E | N/A | |||
| Day Low | $63.72 | EPS | $ | |||
| Volume | 1,341 | |||||
